Yd Bio LTD F-1 registration statements

The S-1’s counterpart for foreign private issuers registering shares for sale in the United States.

NASDAQ

24 Oct 2025

YDES

F-1/A: YD Bio Amends F-1 for Biopharma Public Offering

YD Bio Limited filed an F-1/A amendment detailing its business combination, a PIPE financing, and its strategic focus on cancer detection and eye disease therapeutics.

NASDAQ

23 Sept 2025

YDES

Yd Bio LTD

F-1: YD Bio Completes Merger, Advances Cancer & Eye Therapies

YD Bio Limited has completed its business combination, becoming a publicly traded biopharmaceutical company focused on cancer detection and eye disease treatments, despite reporting a pro forma net loss of $10.5 million for 2024.